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Despite an improved understanding of cancer molecular biology, immune landscapes, 
and advancements in cytotoxic, biologic, and immunologic anti-cancer therapeutics, 
cancer remains a leading cause of death worldwide. More than 8.2 million deaths were 
attributed to cancer in 2012, and it is anticipated that cancer incidence will continue 
to rise, with 19.3 million cases expected by 2025. The development and investigation 
of new diagnostic modalities and innovative therapeutic tools is critical for reducing 
the global cancer burden. Toward this end, transitional animal models serve a crucial 
role in bridging the gap between fundamental diagnostic and therapeutic discoveries 
and human clinical trials. Such animal models offer insights into all aspects of the 
basic science-clinical translational cancer research continuum (screening, detection, 
oncogenesis, tumor biology, immunogenicity, therapeutics, and outcomes). To date, 
however, cancer research progress has been markedly hampered by lack of a genotyp-
ically, anatomically, and physiologically relevant large animal model. Without progressive 
cancer models, discoveries are hindered and cures are improbable. Herein, we describe 
a transgenic porcine model—the Oncopig Cancer Model (OCM)—as a next-genera-
tion large animal platform for the study of hematologic and solid tumor oncology. With 
mutations in key tumor suppressor and oncogenes, TP53R167H and KRASG12D, the OCM 
recapitulates transcriptional hallmarks of human disease while also exhibiting clinically 
relevant histologic and genotypic tumor phenotypes. Moreover, as obesity rates increase 
across the global population, cancer patients commonly present clinically with multiple 
comorbid conditions. Due to the effects of these comorbidities on patient management, 
therapeutic strategies, and clinical outcomes, an ideal animal model should develop 
cancer on the background of representative comorbid conditions (tumor macro- and 
microenvironments). As observed in clinical practice, liver cirrhosis frequently precedes 
development of primary liver cancer or hepatocellular carcinoma. The OCM has the 
capacity to develop tumors in combination with such relevant comorbidities. Furthermore, 
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studies on the tumor microenvironment demonstrate similarities between OCM and 
human cancer genomic landscapes. This review highlights the potential of this and other 
large animal platforms as transitional models to bridge the gap between basic research 
and clinical practice.
Keywords: cancer models, pigs, oncopig, clinical needs, oncology, translational medicine
iNTRODUCTiON
Cancer is a global epidemic causing more than 8 million annual 
deaths worldwide. The more than 13 million new cancer diagno-
ses made each year carry an economic burden of $290B. Cancer 
is expected to be the second leading cause of death in the United 
States in 2017. The American Cancer Society (ACS) estimates 
approximately 1,688,780 new cancer diagnoses will be made 
and 600,920 Americans will die from cancer. The Agency for 
Healthcare Research and Quality (AHRQ) estimates that direct 
medical costs of cancer in the United States in 2014 exceeded $87B. 
Many of these diagnoses, deaths, and costs could be avoided by 
shortening the gap between pre-clinical research and regulatory 
approval for safe and effective therapies. Large animal models 
that closely recapitulate human cancer and comorbid diseases 
represent a critical tool in the global cancer-fighting toolbox.
Cancers are deadliest when diagnosed at late stages, a problem 
that is caused by lack of early detection tests. Cancers of the colon, 
esophagus, liver and intrahepatic bile ducts, lung and bronchus, 
non-Hodgkin lymphoma, oral cavity, ovary, pancreas, and uterine 
cervix are diagnosed at regional or distant stages in more than 50% 
of cases, resulting in poor survival for many patients. The journey 
for advancing cancer diagnostics and therapeutics is both lengthy 
as well as expensive. On average, it takes approximately 8 years, at 
a cost of $1.2B, per approved antineoplastic agent to complete the 
required series of clinical trials leading to regulatory approval. This 
timeline and cost does not include pre-clinical development and 
testing, thereby establishing that the total time from development 
to approval exceeds a decade, per agent. Approximately 10% of 
drugs that begin pre-clinical testing advance into human testing. 
Roughly 75% of research and development costs are attributed 
to failures throughout the drug discovery process, leading to the 
perception that drug discovery and development is one of the 
most precarious financial undertakings in science and biomedical 
research. However, with better models that recapitulate human 
conditions, fewer of these failures may be observed in human 
clinical trial participants. Better models offer the promise of 
shortening the timeline for pre-clinical and clinical trials, as well 
as substantially reducing the cost. Perhaps the most outstanding 
opportunity is to observe such failures in a large animal model, 
saving years in patient accrual to human clinical trials and mil-
lions of dollars to conduct such trials.
The concerns of bringing new drugs to market are recognized 
by pharmaceutical companies, physicians, researchers, and per-
haps most importantly, patients. In recent years, the U.S. Food and 
Drug Administration (FDA) has worked diligently to decrease the 
timelines for approval while increasing the number of new drug 
approvals. Since 2015, 39 new indications on more than 20 newly 
approved drugs have come into effect. In considering a new agent 
for approval, the FDA does not calculate the cost-effectiveness 
of the agent under review. Many newly approved therapies carry 
a substantial cost exceeding $60,000–$120,000 annually, high 
price tags for marginal clinical benefits. Unfortunately, due to 
the lengthy timeline and expensive costs of developing drugs, 
many costs are passed on to insurance companies and patients. 
Utilization of large animal models that best mimic human dis-
eases improves the potential for those agents, which reach human 
trials to have a better chance for success, eventually leading to 
fewer development costs for the market to bear.
With specific regard to cancer therapy, costs are compounded 
as patients eventually fail first-line therapy, thereby moving onto 
second-, third-, and fourth-line therapies, and so on, until treat-
ment options are exhausted. As patients and physicians desper-
ately hope for cures, off-label treatments are frequently employed 
on a case-by-case basis. The army of available antineoplastic 
agents, which has grown substantially following the sequence 
of the human genome, further increases costs while confound-
ing guideline-driven treatment. Pre-clinical or co-clinical large 
animal models play an important role in the process of new drug 
trials and approvals. As the biomedical research community 
works to make the promise of precision medicine a reality, better 
animal models are more critical now than ever before.
Animal models, and specifically mouse models, have played 
a major role in our understanding of the genetic basis of cancer 
and the role of specific genes and gene mutations in the develop-
ment and progression of cancer. However, gaining a complete 
understanding of cancer, which reflects an astonishing number 
of variant diseases, and translating this knowledge to more 
efficacious treatments and cures have been elusive. In a clinical 
landscape that is already challenging, the promise of precision 
cancer medicine serves to further complicate cancer therapeu-
tics. Precision medicine, simply defined as the right treatment 
for the right patient, at the right time, demands highly relevant 
translational models to recapitulate human disease. As clinical 
practice is being driven more and more by molecular pathology, 
the treatment landscape becomes unique for each individual 
cancer patient, rather than cohorts of patients treated as one. This 
review highlights the advantages and disadvantages of currently 
available small and large animal cancer models and introduces 
the Oncopig Cancer Model (OCM) as a qualified alternative to 
currently available cancer models applicable to a wide variety of 
cancer types.
CURReNT SMALL ANiMAL MODeLS
Advances in cancer care are dependent upon the use of pre-clinical 
in vivo model systems to test safety and efficacy. In general, an 
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ideal animal model for biomedical research should: (1) mimic 
the human disease on a molecular basis, (2) derive from a rel-
evant cell line that lends itself to in  vitro study, (3) be reliable 
and predictable, (4) manifest survival differences, (5) allow for 
accurate treatment assessment, (6) be readily imaged, and (7) 
occur in similar background settings as the human disease (1). 
A variety of in vivo systems have been used to study cancer biol-
ogy including the development of genetically modified rodents, 
immunodeficient mouse models engrafted with human tumors, 
and the use of carcinogens and radiation to induce tumors (2–5). 
However, due to vast differences between humans and rodents 
such as mice, the ability to model complex diseases such as cancer 
and translate results to clinical practice is quite limited (6). This 
section focuses on the benefits and drawbacks of currently used 
small animal cancer models.
Mouse Models
Murine models offer several advantages such as the availability of 
a wealth of genetic information, reduced genetic variation, short 
generation intervals, high fecundity, and ease of maintenance 
and handling at a more affordable cost. There are also vast num-
bers of commercially available mouse lines with know genetics, 
making them highly suitable to model a wide variety of human 
diseases. While murine models represent the most commonly 
used small animal cancer models, there are several drawbacks 
associated with their use. Humans are 3,000 times larger than 
mice, live 30–50 times longer and, therefore, undergo about 105 
more cell divisions in a lifetime (7). Without genetic modifi-
cation, mice develop cancers of mainly mesenchymal origin, 
such as sarcomas and lymphomas, whereas humans have a bias 
toward the development of epithelial cancers (carcinomas) with 
age (7). The small size and short lifespan of mice, while advanta-
geous for reducing study times and housing needs, means that 
loss of certain tumor suppressor genes is insufficient to result in 
the development of cancer in a highly penetrant manner, par-
ticularly when such mutations are heterozygous. Accordingly, 
investigators have used the Cre-Lox system to homozygously 
inactivate tumor suppressors in a tissue or cell type-specific 
manner. While this is often sufficient to drive tumor formation, 
such a situation does not mimic the cancer disease progression 
for patients in which rare loss of heterozygosity (LOH), a genetic 
condition in which one copy of a heterozygous genomic region 
(i.e., gene or genetic locus and portion of chromosome) is lost 
due to a mutational event occurs. LOH is a common phenom-
enon in human cancer, which can result in the loss of tumor 
suppressor gene functions through elimination of the allele 
encoding the functional copy of a gene in a subset of cells in 
the body, often leading to the development of a tumor or the 
progression of an existing tumor. Because mouse chromosomes 
are telocentric, LOH often occurs in murine models by loss of 
the entire chromosome carrying the wild-type tumor suppressor 
gene allele in cells heterozygous for a tumor suppressor gene 
mutation (8). However, in human tumors, LOH usually occurs 
via sub-chromosomal deletions covering the wild-type tumor 
suppressor gene locus (9, 10).
On a cellular level, murine cells have lower thresholds for 
genetic and/or epigenetic changes that lead to transformation 
in culture, which further demonstrates fundamental differences 
in the mechanistic properties of cancer development between 
mice and humans (11). Arguably, the most profound difference 
between mouse models and humans is the essentially 100% 
homozygosity of every locus in inbred mouse lines, which makes 
extrapolation back to human populations challenging (12). 
Mouse cells are immortalized much more readily than human 
cells (7). It has also been suggested that mouse cells respond 
to oncogenic Ras expression differently than human cells; RAS 
oncogenes require Ras-like (Ral) signaling in human cells, 
whereas the requirement for this signaling pathway is much 
reduced in Ras oncogene transformation of mouse cells (13). 
Laboratory mouse strains have very long telomeres and express 
Tert, in contrast to human cells (11, 14). Moreover, mice do not 
develop the same forms of genetic instability that human cells 
do during tumorigenesis, perhaps due to their shorter lifespan 
that could restrict the number of sequential mutations that 
accumulate in human tumors (14).
Organ systems also vary between mice and humans such 
that certain types of cancer cannot be accurately modeled. For 
example, anatomical and physiologic variances between the 
mouse and human pancreas make modeling pancreatic cancers 
in mice difficult. The human pancreas is a retroperitoneal and 
segmented organ divided into a distinct head, body, and tail 
(15). In contrast, the mouse pancreas is diffuse, dendritic, and 
poorly lobulated (16). While the vascular supply between mice 
and humans are largely homologous, there are also substantial 
differences in several of the functional cell types between the two 
species. In humans, the exocrine pancreatic acini are organized 
into lobules that secrete to a small, intercalated duct. These then 
drain to larger, interlobular ducts, which then join to form the 
main pancreatic duct. This then joins the bile duct and empties 
to the duodenum. The mouse pancreas has a large interlobular 
duct that drains the three respective lobes. The splenic and gastric 
ducts then merge with the common bile duct and empty more 
proximally to the duodenum (15). The endocrine component of 
the pancreas also differs. While humans have 1,000–3,000 times 
more endocrine islets than mice, humans have a larger propor-
tion of glucagon producing α-cells than mice, who have a larger 
relative percentage of insulin producing β-cells. Human islets are 
also rich with both parasympathetic and sympathetic innerva-
tion and uniformly distributed, while mice have comparatively 
sparse autonomic innervation and random islet distribution (15). 
However, despite these differences, the Pdx-Cre x LSL-KrasG12D- 
Trp53R172H (KPC) mouse has been the benchmark for pancreatic 
cancer research for the better part of a decade (17). By targeting 
expression of KrasG12D and Trp53R172H mutations to the exocrine 
pancreas via the Pdx1 promoter, this model produces reliable and 
clinically relevant cancer histotypes.
Fundamental differences in how tumorigenesis occurs in 
mice and humans also exist. For example, humans carrying one 
mutant and one wild-type allele for the tumor suppressor gene 
APC develop polyps in the large intestine that progressively 
leads to invasive carcinoma. In contrast, mice with the same 
heterozygous state for Apc develop polyps in the small intestine 
that rarely show disease progression (18). Such differences in 
cancer development are due to inherent biological differences 
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between man and mice and are not limited to intestinal polyps 
but are observed in many mouse models of cancer. This is well 
illustrated by variations in tumor spectrum when certain tumor 
suppressor genes known to cause specific cancers in humans are 
knocked out in mice.
The body size limitation of mice makes the development of 
novel imaging modalities and surgical techniques nearly impos-
sible yet these are key techniques needed to diagnose and treat 
a wide variety of tumor types in patients. Moreover, the rate of 
metabolism is substantially higher in mice compared to humans 
(7). These differences mean that the pathways by which tumor 
progression occurs can vary dramatically when comparing mouse 
models to human cancer. As a consequence, the tumors that 
develop in a mouse model may respond differently to therapy. 
For these genetic and physiological reasons, including vast dif-
ferences in drug metabolism and xenobiotic receptors, rodents 
also poorly model toxicity, sensitivity, and efficacy when used 
in pre-clinical drug studies (19). The ability to establish toxicity 
and drug sensitivity pre-clinically in animal models is immensely 
important because less than 8% of cancer drugs translate success-
fully in Phase I clinical trials from animal models (20). While 
mice have provided numerous insights into the biology of cancer, 
their historical limitations emphasize the need to develop new 
models for cancer translational research.
In addition to genetic-based cancer models, induction of 
tumorigenesis via administration of carcinogenic agents is uti-
lized to study cancer in small animal models. However, a major 
disadvantage of this method is the time from administration 
of the carcinogenic agent to tumor formation, which can range 
from 30 to 50 weeks (21). Another route of establishing in vivo 
tumors is xenograft of tumor cell lines into mice. Although this 
mechanism is temporally practical, the ensuing pathogenesis is 
not always representative of human disease (21, 22).
Rat Models
Rats represent another rodent commonly utilized as pre-clinical 
cancer models. In addition to some of the abovementioned 
advantages of murine models, rats have the added benefit of 
larger size, rendering them more amenable to interventions such 
as surgery and radiological imaging (23). Rats are commonly used 
to model colon and bone cancers, largely by exposure to chemical 
carcinogens (23, 24). In addition, surgical manipulations have 
been utilized to develop rat models of metaplastic reflux-induced 
esophageal cancer (25). Recent genome-wide association studies 
in rats have also identified correlations between rat and human 
genetic markers of cancer risk (26). However, these models are 
often limited in their ability to recapitulate human cancer patho-
physiology. For example, transgenic and xenograft-induced rat 
breast cancer models exhibit spontaneous necrosis and failure 
to metastasize (27, 28). In addition, engrafted rat pancreatic 
neuroendocrine tumors (PNET) exhibit increased tumor growth 
following treatment with an mTOR inhibitor, a response that 
contrasts the results of mTOR inhibitor clinical trials (29).
Zebrafish Models
Zebrafish are one of the few non-mammalian species that have 
been extensively utilized as cancer models. As a potential model 
organism, zebrafish exhibit several advantages. The short lifes-
pan and high reproductive capacity of zebrafish render them 
amenable to high-throughput screening for genetic mutations 
(30). In addition, the zebrafish genome shares high homology 
with humans (31), allowing the use of zebrafish tumorigenic 
mutations to gain insights into human tumorigenesis. The 
use of gene-editing techniques including Clustered Regularly 
Interspaced Short Palindromic Repeats (CRISPR) has facilitated 
mutagenesis of numerous gene loci in this highly reproductive 
species (32). Zebrafish cell lines also represent valuable in vitro 
models, including models of broad spectrum leukemia using 
mutant c-Myc transgenic zebrafish (33) and malignant mela-
noma using BRAF mutant zebrafish (34). Nevertheless, zebrafish 
cancer models are not without limitations. Zebrafish exhibit 
great diversity both across and within strains that results in high 
levels of individual-specific variation (31). In addition, genomic 
comparisons between human melanoma patients and zebrafish 
models have identified reduced mutational burden in zebrafish 
tumor cells, suggesting significant differences in genomic stabil-
ity between humans and zebrafish (35). Moreover, attempts to 
model certain cancers including acute myeloblastic leukemia and 
pancreatic carcinoma have either failed to develop or exhibit lim-
ited metastatic capacity (35). Therefore, zebrafish cancer models 
exhibit limitations that prevent their use as consistent models of 
the wide variety of human cancer phenotypes.
Small Animal Hepatocellular Carcinoma 
(HCC) Models
In addition to small animal models that are utilized to model 
many different human cancers, there are animal models whose 
ability to model human disease is limited to one cancer or cancer 
subtype. For example, the rabbit VX2 model is one of the most 
commonly utilized small animal HCC models. In this model, 
virally infected VX2 carcinoma cell cultures are injected into 
rabbits resulting in tumor formation in the rabbit liver (36). 
However, these tumors have unknown biology, varying tumor 
kinetics, and unknown genome organization (36), highlighting 
the limitations of this model as a relevant human HCC model. 
Another drawback of this model is spontaneous tumor necrosis, 
which confounds the evaluation of treatment response after 
pharmacological or interventional treatment. This represents 
a significant drawback for this model, given its use by inter-
ventional radiologists for novel locoregional therapy testing. 
Another commonly used HCC mode is the woodchuck model, 
which produces HCC tumors in response to woodchuck hepati-
tis virus (WHV) infection. WHV infection shares many disease 
characteristics with the human hepatitis B virus (HBV), which 
causes liver cirrhosis and leads to HCC development in humans. 
Similarities between WHV and HBV are seen in the morphol-
ogy of the virus, its life cycle, and the resulting development of 
HCC after 2–4 years of infection (37). This model has been used 
to develop radiofrequency ablation of primary HCC tumors in 
pre-clinical trials (38); however, several limitations exist, includ-
ing differential behavior (woodchuck’s hibernate for a period of 
4–6 months) and variable diet and WHV infection period when 
using wild specimens (39).
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CURReNT LARGe ANiMAL MODeLS
Large animal models of cancer comprise a smaller portion of 
cancer models than small animal cancer models. While small 
animal models offer several advantages such as the availability of 
a wealth of genetic information, reduced genetic variation, short 
generation intervals, high fecundity, and ease of maintenance 
and handling at a more affordable cost, they do not provide the 
anatomical scale required to develop interventional treatments. 
Large animal models such as pigs offer a more anatomically 
similar organism to develop these interventional treatment 
(40–42) and offer cancer cell biology more analogous to human 
cancer cell biology (43, 44). This section focuses on the benefits 
and drawbacks of currently used and up and coming large animal 
cancer models.
Canine Cancer Models
Client owned dogs provide a unique opportunity to study spon-
taneously developing tumors in a context that is beneficial for 
both pets and people. In order to utilize client owned dogs to 
help researchers better understand tumor biology and facilitate 
translation of novel human cancer treatments to clinical set-
tings, the National Cancer Institute’s Center for Cancer Research 
started the Comparative Oncology Program (COP) in 2003.1 Use 
of these animals as comparative cancer models is beneficial due 
to their many biological similarities with humans along with the 
large genetic diversity observed within the canine population. 
Tumors commonly presenting in dogs include osteosarcoma, soft 
tissue sarcomas (STS), lung carcinoma, oral melanoma, mam-
mary carcinoma, oral squamous cell carcinoma, nasal tumors, 
and malignant non-Hodgkin’s lymphoma—likely the best cancer 
model provided by canines because it has considerable analogy 
to the human variant. Canine cancer models are unique because 
they spontaneously present with tumors with several character-
istics similar to those observed in humans (i.e., osteosarcoma in 
large breed dogs) (45). Indeed, cancer occurs naturally in dogs 
with rates reported to range between 5 and 33% (46, 47). It is 
estimated that 45% of dogs 10 and older die of cancer (45), which 
is comparable to the estimated 60% of humans who are diagnosed 
with cancer of the age of 65 years (48). This natural occurrence 
and history of cancer permits the rapid study of DNA damage and 
epigenetic alterations that accumulate over time to result in tumor 
formation, especially given the high homology observed between 
the canine and human genome (49). Because of these advantages, 
researchers have been able to utilize canine cancer models to 
identify relevant genetic alterations and drivers of cancer similar 
to those observed in human cancers. Additionally, canine subjects 
bypass the phases of clinical trial testing, accelerating the pace of 
drug development (50). Many drugs have undergone pre-clinical 
trials using canine cancer models including Resiniferatoxin, a 
drug that acts as an agonist for pain caused by bone cancer, due 
to the canine’s highly noticeable response of self-mutilation of 
areas in pain (51).
There are several disadvantages with using dogs to model 
human cancers. Canine cancer models tend to consist of lymphoid 
1 https://ccr.cancer.gov/Comparative-Oncology-Program.
and sarcoma tumor types as opposed to carcinomas. Cancer drug 
development studies conducted in canines are also not always 
translatable to humans, as dogs have varying drug sensitivity 
compared to humans (52). Another contention surrounding the 
use of canine cancer models in translational research is the issue 
of outbred versus inbred models; because modern dog breeds are 
a product of line inbreeding, their ability to provide a relevant 
model of diverse and heterogeneous human cancers is question-
able (47). Finally, accrual of client dogs to clinical trials—as with 
human patients—presents a barrier to the timeliness of study 
conduct.
Non-Human Primate Models
To date, published reviews or studies on cancer in non-human 
primates are relatively scarce and limited to single case reports 
and small case studies. However, there has been a steady increase 
in the number of reviews published on cancer in non-human 
primates (53–56). These reviews likely represent an increase 
in the recognition of cancer in non-human primates, but they 
also likely represent an increase in the longevity of non-human 
primates maintained in research facilities attributed to factors 
such as improved health care and nutrition and improvements in 
record keeping, including breeding history, genetic background, 
and clinical course of disease.
Potentially, non-human primates offer advantages for study-
ing cancer because of their anatomical, physiological, and genetic 
similarities with humans, being the only bipedal mammalian 
animal model for research and having 1:1 homology with the 
majority of human protein-coding genes (57). It is difficult to 
determine the concordance of toxicities identified in non-human 
primates relative to humans and other species because of a lack 
of clinical data. It is tempting to assume that in response to drug 
delivery, non-human primates will have pharmacological or 
physiological responses most similar to humans; however, this 
sweeping generalization cannot be made (58). Despite the lack of 
evidence, because of receptor and epitope similarity, non-human 
primates may be an appropriate species for testing certain classes 
of drugs, for example, large molecule and biological compounds 
due to the high degree of cross reactivity in those compounds 
between humans and non-human primates (59).
Porcine Cancer Models
Swine cancer models are also highly relevant due to their similar-
ity in size, anatomy, pathophysiology, metabolism, genetics, epi-
genetics, and pathology, as well as their reduced cost compared 
to non-human primate models (60–68). Swine subjects age at 
approximately 3–5 times the rate of humans and have similar 
clinical laboratory and histological findings (66). This life cycle 
permits enough time to develop, characterize, and modulate can-
cer in the swine model from weaning to adolescence (69) but also 
sufficiently short-lived that reasonable research aims and budgets 
can be outlined and accomplished. Advances in DNA sequencing 
and our understanding of the role of non-coding DNA sequences 
have provided insights into the mechanisms underlying altered 
gene expression and other drivers of cancer development. Swine 
genetics in particular lends itself to clinically translatable stud-
ies due to many available outbred lines. The outbred nature of 
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pigs is key in imitating the variety of genetic profiles underlying 
human patient populations and cancer types. In addition, the pig 
genome has high homology with the human genome (70, 71) and 
epigenetic regulation is highly conserved (67). This elucidation 
of the porcine genetic profile combined with advances in genetic 
engineering has permitted the creation of genetically modified pig 
cancer models that not only follow an analogous disease course 
as humans (72) but also respond to cancer drug therapy similarly 
to humans in randomized controlled trials. High-throughput 
genome sequencing and a collection of precision-genetic tools 
combined with tools for bioinformatics analyses and profiling 
of gene expression/proteomics can be applied to pigs (67, 68, 
71, 73–77). The ability to modify mammalian genomes through 
transgenesis, targeted nucleases, and CRISPR, united with the 
development of advanced reproductive technologies including 
cloning, allows researchers to create complex and unique cancer 
models in swine that are more applicable to human malignancies 
(73, 78). Current porcine models utilized for cancer research 
include an APC1311 porcine model of familial adenomatous poly-
posis that produces polyps but not tumors (79), a heterozygous 
TP53 knockout model of spontaneous osteosarcomas (80), and a 
chemically induced porcine HCC model, which takes over 1 year 
to develop clinically relevant tumors (81, 82).
In addition to recent advances in making precise genetic 
modifications to pig genomes, there has been significant progress 
in technologies for testing consequences of genetic changes. 
Imaging modalities such as computed tomography (CT), mag-
netic resonance imaging (MRI), and positron emission tomog-
raphy (PET) can be easily applied to large animals such as pigs, 
whereas application of analogous clinical protocols is difficult 
and impractical using rodents (83). By applying these imaging 
modalities to swine cancer models, detection techniques, pro-
gression monitoring, and therapeutic response assessments may 
be improved. The pig’s size permits radiation-directed therapies 
to be tested and optimized. Surgical resection is the first line of 
therapy and often the standard of care for many cancers. The pig’s 
anatomy allows refinement of surgical techniques and studies of 
local tumor recurrence both of which are difficult or impossible 
to perform in rodents. In addition, tumor natural history is an 
area that is difficult to study in rodents due to their short lifespan, 
about 1/30th that of humans (7). Swine can live up to 10 years, 
thereby enabling researchers to carefully follow the development 
of tumors, tumor progression, invasion, and metastasis in the 
absence of intervention over time. Additionally, the identification 
of biomarkers may be more feasible in these animals due to the 
facile nature of accessing blood and tissue samples, the abundance 
of sample material and the ability to perform longitudinal blood 
sampling over longer periods of time. Understanding tumor het-
erogeneity may be well suited for a large animal, as samples could 
be collected from many different tumors over time and followed 
for variations in somatic mutations, gene expression, epigenetic 
alterations, or differential responses to treatment (66, 78).
One of the main drawbacks of rodent cancer models has been 
their inability to identify safe and effective drugs to treat cancer. 
Mouse cancer models have been poor predictors of drug safety, 
toxicity, and efficacy (84). Furthermore, routes of administration 
in mice are largely limited to intravenous (i.v.), intraperitoneal 
(i.p.), or oral gavage. Pigs have been widely used in pre-clinical 
drug toxicology and are a standard large animal model for pre-
clinical toxicology prior to human studies (63). The size and ease 
in handling pigs allows drugs to be administered in the same 
manner that patients are administered, including orally, i.v., i.p., 
by inhalation, dermal absorption, subcutaneous, intramuscular, 
and transmucosal routes. Longitudinal blood sampling can be 
performed to assess drug exposure and metabolism over long 
periods of time, and the amount of blood samples that can be 
taken from swine in a short period of time enhances the ability 
of pharmacologists to get precise kinetic data following drug 
exposure. There are significant homologies between swine and 
human xenobiotic receptors that regulate drug metabolism and 
pharmacokinetic properties (85). The cytochrome P450 (CYP) 
superfamily of proteins plays a critical role in the processing 
and metabolism of drugs, and again, many studies have shown 
parallels in the structure and function of these molecules in pigs 
and humans (85). Importantly, for pediatric cancer drug studies, 
juvenile pigs have been shown to have similar pharmacokinetic 
responses to certain drugs that cannot be modeled in other 
animals (86). Finally, pigs are easily subject to models of relevant 
comorbidities including non-alcoholic steatohepatitis (NASH) 
and alcohol-induced cirrhosis. The use of pigs in pre-clinical drug 
testing may identify safer and more effective therapies as well 
as establish dosing and routes of administration for new drugs 
prior to human clinical trials. Practically speaking, enrollment 
of pigs to clinical research studies eliminates the accrual barrier 
observed in candidate dogs and human clinical trial patients 
because cohorts of pigs are accessible. Furthermore, a facile por-
cine genome engineering platform enables future humanization 
of drug metabolism in swine models (66).
THe OCM
The OCM is a novel transgenic swine model that recapitulates 
human cancer through development of site and cell specific 
tumors following Cre recombinase induced expression of 
heterozygous KRASG12D and TP53R167H transgenes (87). Details 
regarding the generation of the OCM can be found in Schook 
et al. (87). Briefly, porcine KRAS and TP53 cDNA were cloned 
and site-directed mutagenesis was performed to introduce 
the oncogenic G12D and R167H mutations, respectively. The 
two cDNAs were then introduced into a Cre-inducible vector 
containing a CAG promoter followed by a Lox-Stop-Lox (LSL) 
sequence—which prevents expression of the transgenes until it is 
removed by Cre recombinase—followed by a single copy of the 
KRASG12D and TP53R167H transgenes separated by an internal ribo-
some entry site (IRES) sequence (Figure 1A). Normal Minnesota 
minipig embryotic fibroblasts were transfected with the resulting 
plasmid, and stably transfected cells were used as the source of 
nuclei for somatic cell nuclear transfer (SCNT). A single male 
Oncopig was selected from the resulting litter to develop the 
Oncopig herd (Figure 1B) due to the insertion of the transgene 
construct at a single location on chromosome 18. The breeding 
scheme depicted in Figure 1B allows the production of a herd of 
male and female Oncopigs homozygous for both the transgene 
and an MHC haplotype. The resulting homozygous males can be 
FiGURe 1 | Development and utilization of the Oncopig Cancer Model (OCM). (A) Diagram of the Oncopig transgene cassette located on chromosome 18.  
A Lox-Stop-Lox sequence prevents expression of KRASG12D and TP53R167H. Exposure to Cre recombinase results in site specific recombination between the two 
recognition sites (LoxP), resulting in removal of the Stop sequence and subsequent expression of KRASG12D and TP53R167H. (B) Diagram of the breeding scheme 
used to produce Oncopigs for experimental use. The original male Oncopig homozygous for an MHC haplotype and carrying a single transgene cassette located on 
chromosome 18 is bred to a non-transgenic female to produce offspring heterozygous for the transgene cassette and MHC haplotype. The resulting heterozygous 
offspring are further bred to produce Oncopig offspring homozygous for both the transgene cassette and an MHC haplotype. Male homozygous offspring can then 
be bred to a variety of transgenic or non-transgenic pig breeds (depicted through varying color) to produce genetically diverse Oncopigs for experimental purposes, 
all of which harbor a single copy of the transgene cassette and a shared MHC haplotype.
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bred to a wide range of available pig breeds, allowing the produc-
tion of genetically diverse experimental Oncopigs possessing 
a single copy of the mutated transgenes, the WT alleles, and a 
shared MHC haplotype important for immunological studies as 
described below (Figure 1B).
The KRASG12D and TP53R167H mutations were chosen because 
the resulting amino acid substitutions are commonly found in 
human cancers, with RAS and TP53 mutated in one-quarter 
and one-third of all human cancers, respectively (88, 89). These 
mutations are also observed simultaneously in human cancers, 
making this a highly relevant model from a genomics perspec-
tive. Utilization of two mutations commonly observed in human 
tumors allows production of tumors driven by the same molecular 
alterations as humans in a species with similar anatomy, physiol-
ogy, metabolism, and genetics. In addition, the heterozygous 
outbred nature of the OCM means that this model more closely 
mimics the human condition in comparison to commonly used 
inbred, homozygous germline mouse models. This model, as a 
transitional animal model from mice or other small animals to 
humans, fulfills the currently unmet clinical modeling needs for 
relevant investigation of both hematologic and solid tumor can-
cers. With its genetic malleability and predictable behavior, the 
OCM offers a comprehensive toolset for modeling both human 
cancers and comorbid disease. Together, this makes the OCM 
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an ideal platform to develop a wide range of cancer models to 
test new treatments, develop standards, and improve early detec-
tion rates. The OCM is a transformational research tool for the 
investigation of therapeutic efficacy while significantly reducing 
the costs, variables seen in human subjects, and lengthy conduct 
of human clinical trials. The following sections discuss progress 
made to date on modeling various cancer types in the OCM.
Soft Tissue Sarcomas
Soft tissue sarcomas are a group of rare mesenchymal tumors 
that carry a 5-year survival rate of 50%. STS consist of over 50 
subtypes and arise from a number of tissue types including fat, 
muscle, blood vessels, and nerves (90). As the survival rate for 
STS has remained unchanged for decades, there is a critical need 
for further research into STS characterization and treatment. This 
research is currently limited by the availability of STS cell lines 
and tissue samples (91), highlighting the need for transitional STS 
models for improved STS detection, diagnosis, and treatment. 
As TP53 represents one of the most frequently mutated genes 
in human STS (92, 93), the OCM represents an ideal model to 
develop STS cell lines and in vivo models critical for improving 
survival rates for patients with STS. To date, both STS cell lines 
and in vivo STS tumors have been developed and characterized 
in the OCM (76, 87).
Utilization of human tumor cell lines is critical for expanding 
our understanding of tumor biology and developing new can-
cer therapies (94). However, given the high number of diverse 
human STS subtypes and limited cell line availability, additional 
STS model cell lines are required to investigate the mechanisms 
underlying variable targeted therapy responses observed across 
STS subtypes (91, 95). As an initial proof of concept to demonstrate 
the ability to transform Oncopig mesenchymal cells, fibroblasts 
isolated from Oncopig skin biopsies were transformed via expo-
sure to Cre recombinase in vitro (87). The resulting STS cell lines 
expressed both KRASG12D and TP53R167H transgenes and displayed 
tumorigenic phenotypes, including altered morphology, reduced 
cell cycle length, increased cell migration, and soft agar colony 
formation (87). Injection of the STS cell lines in SCID mice 
resulted in tumor formation (87), and transcriptional profiling 
of Oncopig STS cell lines via RNA-seq identified transcriptional 
hallmarks of human STS, including altered TP53 signaling, Wnt 
signaling activation, and evidence of epigenetic reprogramming, 
including altered expression of DNA and histone methyltrans-
ferases (76). In addition, FOSL1, a key transcriptional regulator 
of human STS, was identified as a master regulator in the Oncopig 
STS cell lines (76), further demonstrating the similarities between 
Oncopig and human STS at the molecular level. These in vitro 
phenotypes and transcriptional profiles are consistent across 
replicates and in lines cultured for extended periods of time (76), 
highlighting the stability of Oncopig cell lines. As the OCM sup-
ports the transformation of any cell type, it provides a platform 
for the production of stable STS cell lines originating from a wide 
variety of mesenchymal cell types for in vitro STS research.
While cell lines are useful for understanding fundamental 
tumor biology and testing potential new therapies, in  vivo 
transitional models are also critical to translate basic in  vitro 
discoveries into clinical practice. STS tumor formation has been 
successfully demonstrated via direct injection of adenoviral 
vector encoding Cre recombinase (AdCre) into Oncopig skeletal 
muscle, resulting in tumors blindly pathologically characterized 
as leiomyosarcomas (76, 87, 96). These tumors develop rapidly 
and consistently and also recapitulate transcriptional hallmarks 
of human leiomyosarcomas, including altered TP53 signaling, 
Wnt signaling activation, and evidence of epigenetic reprogram-
ming (76). Master regulators of Oncopig leiomyosarcomas were 
also consistent with human leiomysoarcomas, including MEF2C, 
which acts as a tumor suppressor in human leiomyosarcoma 
(97). The Oncopig leiomyosarcoma model therefore represents a 
qualified alternative tumor model for pre-clinical treatment and 
imaging testing, as well as an ideal training tool for surgical and 
procedural specialties. In fact, the OCM is already being utilized 
for device testing. Using the Oncopig leiomyosarcoma model, 
researchers have tested the efficacy of 3D spatially registered real-
time image-guided catheter-based ultrasound (CBUS) thermal 
ablation therapies (96). By inducing leiomyosarcoma formation 
and then treating these tumors, the ability to utilize 3D tracked 
ultrasound image guidance to precisely place catheters and treat 
tumors was demonstrated, resulting in complete ablation of the 
tumor (96). This demonstrates the ability to utilize the OCM as a 
pre-clinical model for device testing not possible in small animal 
models.
Pancreatic Cancer
Despite modest improvements in recent years, pancreatic cancers 
remain highly lethal with an overall 5-year survival of 8% (98). 
Genetically modified mice have allowed tremendous insights into 
disease etiology, particularly on a genetic level, as well as in vivo 
characterization and mechanisms. The KPC mouse model has 
been the gold standard for pre-clinical pancreatic cancer research 
for over a decade. Yet, such models are limited in scope for more 
direct translational application to humans regarding epigenetic 
events and therapies given their anatomical and physiological 
variances compared to humans. Given the greater anatomical and 
physiological similarities between pigs and humans, an Oncopig 
pancreatic ductal adenocarcinoma (PDAC) model will provide 
a more clinically relevant model, allowing insight into surgical 
and interventional radiology techniques not possible in currently 
used mouse models. While such a porcine model is certainly not 
without limitations, the domestic pig may more faithfully reca-
pitulate human PDAC and expand our understanding of disease 
pathology beyond what is possible using current small animal 
PDAC models.
A porcine PDAC model is currently being developed using 
the OCM. Successful induction of both predominant pancreatic 
cancer histotypes—exocrine and neuroendocrine—via direct 
delivery of AdCre to the main pancreatic duct has been demon-
strated in the OCM. This approach led to locally invasive disease 
sharing histological hallmarks of human PDAC including a dense 
fibroblastic stroma and acinar-to-ductal metaplasia (99), which 
may provide a more clinically relevant model than currently used 
small animal PDAC models. This is particularly important for the 
neuroendocrine component, which is relatively underrepresented 
in research compared to exocrine/ductal cancers. Murine models 
of PNET produce a variety of PNET types with varying behaviors 
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ranging from indolent to highly aggressive (100, 101). While these 
models have proved to be valuable prototypes of disease, they are 
limited in the extent to which they can represent human PNET. 
The low incidence and heterogeneous presentations of PNET 
itself combined with the low availability of pre-clinical models 
have slowed progress in terms of early diagnosis and the develop-
ment of targeted therapies. In fact, one of the most significant 
clinical challenges in the management of pancreatic caner is its 
late presentation, demonstrated by the diagnosis of more than 
80% of pancreatic cancer cases at regional and distant stages. As 
stage is the key prognostic factor in pancreatic cancer survival 
(98), a means of improved early detection is extremely attractive 
to clinicians. Given the size and orientation of the pig pancreas, 
near identical imaging modalities can be used to longitudinally 
follow disease progression immediately after induction in the 
Oncopig PDAC model, which may improve our understanding 
of early events in the carcinogenic process and facilitate earlier 
detection.
Furthermore, the Oncopig PDAC model also allows investiga-
tion into several clinical avenues that are not possible or must be 
significantly altered to perform in rodents. For instance, patients 
with locally surgically resectable tumors have improved survival 
compared to those with inoperable disease (98). However, in 
rodents, the study of many novel surgical techniques is impos-
sible due to the differences in size and anatomy. In this capacity, 
the Oncopig PDAC model may allow investigation of new surgi-
cal interventions as well as nanotechnology and localized drug 
delivery methods for pancreatic cancers.
HCC and Comorbidities
Worldwide, HCC is the fifth most common cancer and the third 
most common cause of cancer-related deaths, occurring more 
often in men than in women. In the United States, 40,710 new 
cancers of the liver and intrahepatic bile duct are expected in 
2017, with an estimated 28,920 deaths. HCC is the main form of 
primary liver cancer that carries a 5-year survival rate of 17.5%. 
This low survival rate is predominantly due to the low number 
(15%) of patients who are eligible for surgery or other curative 
therapies at the time of diagnosis (102), highlighting the need 
for improved HCC early detection and treatment strategies. 
A number of locoregional therapies (LRTs) including cryoabla-
tion, radiofrequency ablation, and transarterial chemoemboliza-
tion are currently used to treat HCC patients who are ineligible 
for surgery; however, the optimum treatment strategy is dictated 
by the physician’s specialty as opposed to evidence-based 
consensus (103). This highlights the need for improved HCC 
animal models to test LRTs and combination therapies to better 
understand the intrinsic tumor biology underlying differential 
treatment responses. An Oncopig HCC model would provide 
an ideal transitional model to address this need as well as refine 
techniques to help improve early detection rates.
The OCM, as an HCC investigational tool, offers a novel, 
physiologically and anatomically relevant cancer model for which 
a multitude of innovative therapeutic modalities can be applied 
and tested. This model is a critical transitional, translational, and 
transformational research tool for the investigation of therapeutic 
efficacy, variables seen in human subjects, and lengthy conduct of 
human clinical trials. Importantly, it can be utilized to conduct 
correlative studies for more efficient and consistent investigation 
of new therapies. Its size allows utilization of the same methods 
and instruments used in human clinical practice, and the seg-
mental nature of the pig liver (similar to human anatomy) allows 
each Oncopig to serve as its own therapeutic control. Although 
the information gained from human clinical studies has been 
used to marginally enhance the efficacy of current standard of 
care LRTs, such trials have provided only limited capability for 
the investigation of the fundamental processes contributing to 
procedure effectiveness and disease relapse.
An Oncopig HCC model has been initiated to serve as a 
transitional model linking murine results with clinical outcomes. 
Oncopig HCC cell lines have been created by isolating hepato-
cytes from Oncopig livers followed by in  vitro transformation 
(77). These cell lines recapitulate human HCC characteristics, 
including an epithelial-mesenchymal transition, secretion 
of alpha-fetoprotein (AFP), and transcriptional similarities 
including TERT reactivation, apoptosis evasion, angiogenesis 
activation, and Wnt signaling activation (77). In addition, direct 
comparison between Oncopig and 18 commonly used human 
HCC cell lines revealed conservation of master regulators of gene 
expression (77). The Oncopig HCC cells also form hypervascular 
tumors histologically characterized as Edmondson Steiner grade 
2 HCC with trabecular patterning when implanted into both 
SCID mice and Oncopigs subcutaneously (77). In addition, 
T-lymphocyte infiltration is observed, indicating that these are 
“hot” tumors potentially appropriate for immunotherapy tri-
als. This is an important aspect of this model, as it is clear that 
HCC-specific antigens are recognized by the immune system and 
contemporary clinical studies have indicated that manipulating 
the immune response can be deleterious to HCC tumor growth 
(78). Together this suggests that the Oncopig HCC model is a 
qualified alternative for improving HCC detection, treatment, 
and biomarker discovery.
In addition to the formation of clinically relevant tumors, an 
ideal HCC animal model must also mimic relevant comorbidities 
observed in humans. Alcoholic liver disease and NASH represent 
common chronic liver ailments, both of which are progressive 
and incite liver cirrhosis—a precancerous state of liver scar-
ring—that increases the risk for HCC development. A protocol 
for the induction of alcohol-related liver cirrhosis within 8 weeks 
using intravascular administration of an ethanol-ethiodized 
oil emulsion via the hepatic artery has been successfully tested 
and validated in the OCM (77). This provides the opportunity 
to assess the role of chronic alcohol-induced liver cirrhosis in 
HCC tumorigenesis. In addition, researchers have utilized the 
Ossabaw pig to generate a porcine NASH liver disease model 
(104). As Ossabaw pigs are genetically predisposed to obesity 
and diabetes, exposure to a “Western” or “NASH diet” results in 
the development of severe metabolic syndrome with markedly 
abnormal liver histology that closely mimics human NASH within 
8–24  weeks (104). While this represents a promising porcine 
NASH model, natural progression to HCC would take years to 
develop. However, crossbreeding the OCM and Ossabaw would 
result in a unique “Oncobaw” cross characterized by capacity for 
inducible tumors as well as development of NASH liver disease, 
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providing a distinctive platform to study HCC in the NASH liver 
microenvironment.
Oncopig immunological Profiling
The hallmarks of cancer have recently been updated to include 
the ability of cancer cells to avoid immune recognition and 
subsequent destruction (105). The impact of having immune cell 
infiltrates at the tumor site has especially been evaluated in colo-
rectal cancer patients, where intratumoral T cells with cytotoxic 
nature and memory phenotypes allowed prediction of prognosis 
for patients at an early stage of disease (106). In addition to the 
type of immune cell infiltrates, the outcome for colorectal cancer 
patients was also found to be dependent on both the density and 
location of the immune cells within the tumor (107). Together, 
these three concepts formed the basis of the Immunoscore, which 
has already become an integrated part of the prognostic approach 
for colorectal cancers in humans (108). The mechanisms underly-
ing the ability of the cancer cells to avoid immune destruction 
have been proposed to differ dependent on the degree of immune 
cell infiltrates (109). For this reason, an immunological charac-
terization of the OCM tumor landscape is considered crucial 
to subsequently use this information for design of pre-clinical 
immunotherapeutic studies. Recently, both infiltration of several 
T-cell subsets within OCM tumors and endogenous anti-tumor 
immune responses have been demonstrated (Overgaard et  al., 
2017, submitted). This indicates that the OCM develops “hot” 
tumors and a porcine version of the Immunoscore will indeed 
be both interesting and useful when selecting which therapies to 
test in the OCM. Adaptation of an in vivo cytotoxicity assay in 
line with what has previously been demonstrated for mice and 
monkeys (110–112) would allow a direct measure of anti-tumor 
cytotoxic immune responses and identification of epitopes 
involved in the cytotoxic recognition of tumor cells. While T-cell 
infiltration has been observed in Oncopig tumors developed via 
either AdCre or transformed cell line injection, comparisons of 
the resulting tumor heterogeneity and immune microenviron-
ments induced by the two tumor formation methods have not 
been performed. These future comparisons will be important for 
ensuring Oncopig tumor heterogeneity, the surrounding micro-
environment, and subsequent immunological responses mimic 
those observed in humans.
In addition, adoptive transfer of T cells between MHC-matched 
Oncopig littermates is now a possibility with the development of a 
NGS-based approach for porcine MHC class I allele typing (113). 
Those animal pairs suddenly enable adoptive T-cell therapies to 
be tested in a large and fully immunocompetent animal model. 
Finally, in addition to the adaptive immune system, the porcine 
innate immune system has been heavily studied and found to be 
similar to humans in terms of anatomy, organization, and response 
(114). For example, pattern recognition receptors such as toll-like 
receptors (TLRs) have been heavily studied in pigs (115–117), 
providing insights into their evolution, variability across breeds, 
and similarities with humans. In addition, vast knowledge regard-
ing porcine cellular and humoral innate immune responses and 
their similarities with humans exist (114). While this work has 
not been performed in the Oncopig, the extensive knowledge of 
both the porcine adaptive and innate immune system represents 
a significant advantage for this and other porcine cancer models, 
given the emerging role of the immune system in tumor develop-
ment and treatment.
UTiLiZiNG THe OCM TO ADDReSS 
UNMeT CLiNiCAL NeeDS
Animal research has played a vital role in advancing biomedical 
science. However, laboratory animals may experience significant 
adverse effects as a result of experimentally induced cancers and 
the effects of investigative or treatment regimes are substantial 
(118, 119). Therefore, the use of animals in research comes with 
ethical responsibilities (120). The three R’s (Reduce, Replace, and 
Refine) as defined by Russell and Burch (121) provide a practical 
strategy for applying an ethical framework to animal research. 
These guiding principles indicate that researchers must seek to 
(1) replace animal use with alternative techniques, (2) reduce 
the number of animals used to the minimum required to obtain 
meaning information, and (3) refine experimental procedures to 
ensure animal suffering is reduced as much as possible.
Consistent with the three Rs, the Oncopig model allows the 
discrete induction of localized tumors that can be closely followed 
to meet scientific objectives while minimizing comorbidities and 
mortality. However, in order for the OCM to be utilized to its full 
potential, an understanding of how the various Oncopig-based 
cancer models can be applied to specific unmet clinical and pre-
clinical human cancer needs is required. This section describes 
significant and pressing unmet clinical needs that (1) need to be 
addressed to improve disease burden and survival rate and (2) can 
be effectively addressed by utilizing the OCM as a translational 
model to bridge the gap between small animal models and human 
clinical trials.
early Detection
As the biomedical research community investigates the diag-
nostic and prognostic value of liquid biopsies, a large animal 
model becomes increasingly important for both metabolic 
similarities and ease of sampling. Candidate biomarkers from 
serum, plasma, or peripheral blood must be accurately and 
reproducibly measurable, clinically feasible, cost-effective, and 
prospectively validated in randomized clinical trials. Due to the 
inducible nature of the OCM, this model represents an ideal large 
animal model for the identification of candidate early detection 
biomarkers. Figure 2 outlines a variety of biomarkers that have 
been validated in the clinic and can be more rigorously tested 
in the OCM. Putative biomarkers in blood consist of soluble 
factors such as serum proteins and circulating tumor DNA, or 
other cellular factors such as tumor cells, T-cell subsets, and other 
immune cell populations. The serum factors may be single or 
could include a panel of factors preferably measured by a single, 
validated assay. To date, most published analyses of peripheral 
blood biomarkers in immunotherapy have been retrospective 
and hypothesis generating, although important information has 
been gained that illuminates the mechanisms of clinical benefit 
with some approaches and has helped inform subsequent clinical 
trial design.
FiGURe 2 | Utilization of the Oncopig Cancer Model (OCM) for biomarker discovery and validation. (A) Tumor and blood samples are taken from Oncopigs for 
biomarker screening studies. Samples are processed immediately (fresh), flash-frozen, or formalin-fixed paraffin-embedded (FFPE). Blood samples can immediately 
undergo Ficoll density centrifugation for isolation of peripheral blood mononuclear cells (PBMCs). Fresh tumor samples can be used to produce tumor cell lines and 
isolate tumor-infiltrating lymphocytes (TILs). The flash-frozen samples can be used for deep sequencing (i.e., whole-exome sequencing, RNA-seq, miRNA-seq, and 
DNA methylation analysis). FFPE samples can be utilized for immunohistochemistry (IHC) of the tumor and the tumor microenvironment. Results obtained from these 
analyses can be correlated with patient outcomes to identify predictive biomarkers. (B) Proposed testing of clinical management with immunotherapy. As new 
immunotherapy agents and combinations are developed, optimal combinations and subtype susceptibility must be determined. Patients experiencing durable 
responses that are sustained even off treatment require new concepts in risk management and mitigation, while making the most of the clinical benefit. Overall, a 
phased approach can be tested in which aggressive combination regimens that achieve frequent responses can be followed by maintenance with less aggressive 
and safer regimens, reaching the point of weaning responsive animals off treatment. Identifying biomarkers will be crucial for optimal clinical management. Adapted 
from Ref. (122).
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TABLe 1 | Potential predictive biomarkers for immunotherapy.
Type Source Biomarker Clinical significance
Liquid Serum IL-6 High-dose IL-2 treatment failure and shorter overall survival associated with high levels in 
metastatic renal cell carcinoma
CRP High-dose IL-214 resistance associated with high levels; decreasing levels during ipilimumab 
therapy associated with disease control and survival
VEGF Lack of response to high-dose IL-2 is associated with high levels and decreased overall survival
LDH Ipilimumab therapeutic benefit predicted by low pretreatment levels; decreasing levels during 
ipilimumab therapy associated with disease control and survival
sCD25 Ipilimumab therapy resistance predicted by high levels
NY-SEO-1 antibody Greater likelihood to respond to CTLA-4 blockade predicted by seropositivity
Cellular Peripheral blood Neutrophils/leukocytes High-dose IL-2 treatment failure and shorter overall survival associated with high counts
Lymphocytes High-dose IL-2 therapy response associated with immediate lymphocytosis
CD8+ T cells Clinical benefit to CTLA-4 blockade associated with presence
Absolute lymphocyte count Increasing counts during ipilimumab therapy associated with improved overall survival
Eosinophils Increasing counts during ipilimumab therapy associated with improved overall survival
CD4 + ICOS + T cells Increase in frequency after ipilimumab therapy
Myeloid-derived suppressor cells Ipilimumab therapy benefit predicted by low frequency
Tumor PD-L1  
Tumor-infiltrating 
lymphocytes
CD4 + ICOShigh T cells Clinical benefit of ipilimumab correlated with increased frequency
CD8 + T cells PD-1/PD-L1 expression predicts response to PD-1 blockade
Genomic Tumor Tumor mutation loads Predicts clinical benefit of ipilimumab and PD-1 blockade
Mismatch repair Predicts clinical benefit of PD-1 blockade
Adapted from Ref. (132).
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immunogenicity and immunotherapy
After decades of research, the hope of effective immunotherapy 
for solid tumors became a reality with the development of immune 
checkpoint inhibitors (78, 123). This elegant approach leverages 
the immune system, which has the capability to recognize a 
diverse array of both foreign and tumor-derived antigens, to exact 
a tumor-specific response capable of arresting malignant growth. 
Novel immunotherapeutic regimens that both counteract these 
immunosuppressive mechanisms and amplify tumor-specific 
immunity have the potential to profoundly improve clinical out-
comes for cancer patients. The recent demonstration that cancer 
immunotherapy extends patient survival has reinvigorated 
interest in elucidating the role of immunity in tumor pathogen-
esis. Since ipilimumab entered the treatment landscape in 2011, 
immunotherapy has continued to revolutionize cancer therapy. 
In fact, immunotherapy was named the American Society of 
Clinical Oncology (ASCO) top cancer advance of the year for 
2016 (124). A number of U.S. FDA-approved agents have become 
available for an increasing number of difficult-to-treat cancers, 
such as melanoma, renal cell carcinoma (RCC), HCC, and lung 
cancer, among others. In contrast with most chemotherapy 
and targeted therapies, immunotherapy offers the possibility 
of durable responses, sometimes even without continued treat-
ment (125–127). However, objective responses among patients 
treated with single-agent regimens are seen in less than one-half 
of patients treated. Combination of immune checkpoint inhibi-
tor therapy raises response rates but also increases toxicity and 
cost (128). Thus, to optimize selection of appropriate patients 
for immunotherapy and avoid unnecessary toxicity and health 
care costs, there is a clear need to identify truly predictive, and 
not simply prognostic, biomarkers of response. The OCM can 
address some of the issues regarding selection of agents and 
expected immune responsiveness as novel agents are developed.
Understanding which factors predict clinical benefit with 
immunotherapy in a relevant animal model can improve the 
selection of tumor types and patient subsets who will respond, 
illuminate the mechanism of action of novel immunotherapeutic 
approaches, and potentially inform which patients require 
single-agent versus combination strategies (Table 1). Examples of 
biomarkers in the immunotherapy landscape include (1) soluble 
factors such as serum proteins, (2) tumor-specific factors such as 
receptor expression patterns and components of the microenvi-
ronment, (3) identification of immune cell subsets such as Treg, 
and (4) host genomic factors (129–131). Despite the interest in 
biomarker development for immunotherapy, validated biomark-
ers have remained an elusive goal and the availability of the OCM 
enables biomarker validation of serum, immune cell, tumor, and 
tumor microenvironment to be correlated with response.
Our incomplete understanding of the mechanisms of action 
of specific immunotherapies makes it difficult to identify a sur-
rogate marker that adequately captures the process across differ-
ent classes of drugs (133). Many published analyses of potential 
predictive biomarkers for immunotherapy are retrospective, with 
limited extension into large prospective trials. In addition, there 
has been substantial variability in standardization, measurement, 
and interpretation of early biomarker assays (134). Furthermore, 
biomarker development in immunotherapy is challenged by the 
fact that immunotherapy targets are often inducible and dynamic 
13
Schachtschneider et al. The Transitional OCM
Frontiers in Oncology | www.frontiersin.org August 2017 | Volume 7 | Article 190
over time and location. This is a function of the complex tumor 
microenvironment and the contribution of immuno-editing to 
the immune milieu. The tumor microenvironment involves com-
plicated interactions between several types of infiltrating immune 
cells such as monocytes, neutrophils, dendritic cells, T and B cells, 
eosinophils, basophils, mast cells, and natural killer cells, as well 
as the heterogeneous tumor cells themselves and their companion 
stromal cells, including tumor-associated macrophages, fibro-
blasts, adipocytes, endothelial cells, and others (135). The local 
environment is further complicated by “micro-niches” created 
by alterations in perfusion, oxygenation, electrolyte levels, and 
the subsequent development of resistant tumor cells surviving 
in nutrient- and oxygen-deprived conditions (135, 136). Thus, 
these micro-niches likely represent distinct microenvironments 
with different cell types and factors, all within one tumor deposit. 
Finally, incomplete immune editing may result in selective pres-
sure on tumor cells, resulting in resistant tumor cell clones and 
immune escape (132, 135).
Despite these challenges, clinical research of immunotherapy 
over the last several years has confirmed the importance of 
tumor-infiltrating lymphocytes as both prognostic and predic-
tive indicators for patients with cancer and for treatment with 
immunotherapy. There have also been several trials of T-cell 
checkpoint inhibitors in which PD-L1 expression in the tumor 
microenvironment has been associated with more favorable 
outcomes, although this has not been uniformly demonstrated. 
Other groups have used a larger panel of gene signatures, includ-
ing Treg, CD8, cytokines, chemokines, and other factors, that 
correlate with therapeutic responses. These studies collectively 
suggest that there may be host, tumor, and immune factors that 
can be used for biomarker development. The importance of the 
tumor microenvironment has been appropriately stressed, but, 
practically, the ability to use serum or peripheral blood biomark-
ers is challenging and would be bolstered through utilization of 
the OCM.
Therapeutic Screening and Development
During early drug development, the primary goal of testing is 
to determine if the compound exhibits pharmacological activity 
that justifies commercial development. If so, the drug then moves 
into testing for safety. Minimum requirements for drug toxicity 
testing in non-clinical studies are regulated by agencies such as 
the FDA in the USA, the Committee for Medicinal Products for 
Humane Use in Europe, and the ministry of Health, Labor and 
Welfare in Japan. Common expectations for these agencies are 
provided by the International Committee on Harmonization 
(ICH2), which has developed standards for acceptable practices in 
drug development. ICH requires toxicity testing in two relevant 
animal species (137). Relevant animal species usually include 
one rodent, either a rat or mouse, and one large animal species. 
However, many of the available pre-clinical animal cancer models 
offer limited benefit for therapeutic screening, dosing, and devel-
opment due to their lack of similar size and drug metabolism 
compared to humans.
2 http://www.ich.org/home.html.
Several factors are considered when selecting the large animal 
species. Ethical and legal considerations encourage use of the 
lowest sentient species that will accomplish the scientific goals 
(121). Other criteria used in selecting a species include the 
generation of a similar metabolic profile to humans, appropriate-
ness of the species for use in the laboratory environment, prior 
history of the species with similar classes of drugs, historical 
database, genetic and phenotypic variability of the species, and/
or breed, ease of handling, source, and supply. Swine are not 
typically used during early drug development because of their 
large mass and the relative lack of drug until production scales 
up (138). However, swine have been used in safety assessment 
and are increasingly used because of similarities to humans in 
cardiovascular anatomy and physiology, integumentary system, 
digestive system, renal system, and immune system (139). The 
porcine PXR gene regulates hepatic genes involved in metabolism 
and transport. PXR activates CYP3A, which is involved in more 
than 50% of xenobiotic metabolism, by binding to its regulatory 
region. The porcine PXR gene is 87% homologous to human PXR, 
which represents a significant advantage compared to the 77% 
homology observed between human PXR and mouse Pxr. The 
OCM therefore represents an ideal model for the investigation 
of absorption, distribution, metabolism, excretion, and toxicity. 
In addition, the similar size between the OCM and humans, in 
contrast to small animal models, allows more accurate testing 
of optimal dose in a pre-clinical setting. Finally, as cancers in 
humans develop over many years on the background of comorbid 
disease, utilization of the OCM enables therapeutic screening and 
development in a setting closely mimicking molecular and clini-
cal backgrounds. Therefore, the OCM represents an ideal model 
for the investigation of drug metabolism and toxicity predictive 
of human outcomes.
Prognostic indicators
In an ever-changing world of medical research and disease 
treatment, prognostic indicators evolve as treatment avenues 
evolve. One key unmet clinical need that biomedical models 
can bridge is the investigation of prognostic indicators, thereby 
allowing clinicians to more accurately forecast patients’ 
benefits resulting from treatment. As mentioned earlier, the 
OCM allows ample biospecimen (blood, saliva, urine, tissue, 
etc.) sampling and analysis. Furthermore, given the outbred 
nature of this model and the adequate supply, the OCM allows 
cohort investigation, which can provide sufficient unique 
analysis and volume to determine such prognostic indicators as 
progression-free survival (PFS) and time to progression (TTP). 
Based on the incidence of comorbid diseases, such as alcoholic 
cirrhosis and NASH, the OCM will allow precise diagnosis and 
prognostication.
improved imaging
The importance of diagnostic imaging in both research and treat-
ment cannot be overstated. Medical imaging, in clinical practice, 
is used to diagnose, assess, and prognosticate patients’ health over 
time. The size and anatomy of the OCM provides the ability to eas-
ily image—with various modalities including CT, MRI, PET, and 
ultrasound—in a similar setting as clinical practice. As a model of 
TABLe 2 | Oncopig cell isolates successfully transformed in vitro.
Cell type/origin isolated Transformed
Fibroblasts Yes Yes
Hepatocytes Yes Yes
Pancreatic ductal cells Yes Yes
Dermal epithelial cells Yes Yes
Splenocytes Yes Yes
Ovarian surface epithelial cells Yes Yes
Fallopian tube secretory epithelial cells Yes Yes
Renal proximal tubule epithelial cells Yes Yes
Bone marrow (no specific cell isolation) Yes Yes
Testis (no specific cell isolation) Yes Yes
Skeletal muscle (no specific cell isolation) Yes Yes
List of OCM cell types for which isolation and transformation have been attempted.
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disease, OCM imaging can be correlated with physical dissection 
to validate imaging findings, which cannot be done in human 
patients. Furthermore, the long lifespan and relatively low cost 
of the OCM permits frequent imaging and longitudinal studies 
from premalignant through metastatic disease states, which can 
assist in prognostic assessment and therapeutic response evalua-
tion. The similar anatomy of the OCM allows deep investigation 
of angiographic imaging, which is limited or impossible in small 
animal models but is important for inducing disease as well as 
therapeutic research, as discussed in the following section.
Device Testing and Surgical Practice
Advancements in surgical technologies are necessary to improve 
outcomes for patients; however, pre-clinical models in which 
to test new strategies are limited. One aspect of testing new 
techniques or devices is the engineering capabilities or technical 
feasibility of the instrument or procedure; however, equally as 
important are the ergonomics and ability to translate the findings 
to human patients. Thus, selecting the appropriate animal model 
is one of the most important components of pre-clinical testing 
for these indications, and the animal model chosen should reflect 
the target patient population.
For a surgical device, technique, simulation, or practice, it 
is imperative that the anatomy, physiology, and disease state of 
the animal be similar to humans. As the size of medical devices 
and instruments used are optimized for human sized organs, a 
large animal model is ideal within ethical, safety, and financial 
considerations. Given the similarity of size of the swine organs, 
skin characteristics, and physiology/immunity; porcine models 
have become standard in multiple settings including cardiac/
atherosclerosis (140), hernia, foregut, transplant (141), hepatobil-
iary (142), and minimally invasive surgery training and research 
programs (143, 144). As pigs are true ominvores, the physiology 
of digestion and liver metabolism are quite homologous, thus 
rendering the pig a valuable model for translational surgical 
research. However, what has been missing up until this time is a 
reliable model in which cancer treatment and resection could be 
tested. Though clearly this is valuable for an anti-tumor systemic 
treatment model, it is invaluable for the surgeon who wishes to 
test a catheter-based, resection-based, or technical procedure 
since the same instruments used in the human can be utilized in 
the animal. Furthermore, the OCM allows realistic tumor mod-
eling in which tissue characteristics as a result of tumor growth 
are reliably recreated and margins can be assessed, both of which 
have been difficult to model by either orthotopic injections or 
biomaterial injections (145).
The OCM platform has already been applied to establish STS, 
HCC, and PDAC in target organs and, using the same sequence 
of gene mutations, is being used to create colon and other cancer 
models. Open, laparoscopic, and robotic liver, stomach, pan-
creas, small bowel, colon, and gallbladder resections have been 
performed on the OCM using the same instruments, devices, 
and techniques used in humans, including vascular staplers and 
energy devices. The size of sutures used in the OCM is the same as 
humans, and tissue characteristic are near identical from a surgi-
cal perspective. Therefore, we see the OCM as an ideal model 
for surgical technique and device testing in the management of 
cancers in multiple organs, recapitulating the human situation 
and allowing realistic and accurate practice in an animal model.
Development of Standards
The importance of standards development in the field of 
medical research is understood by veterinary and human clinical 
researchers alike. The National Cancer Institute supports stand-
ards’ development throughout the cancer continuum, including 
such initiatives as the Veterinary Cooperative Oncology Group 
(VCOG), the cancer Data Standards Registry and Repository 
(caDSR), the National Clinical Trials Network (NCTN), and 
the Genomic Data Commons (GDC), to name a few. Standards, 
which can refer to data elements, data types and formats, pro-
grammatic interfaces, and operating procedures, enable potential 
data sharing across institutions, diseases, and research studies. 
With this in mind, the OCM platform was designed to develop 
and adhere to standards from the beginning. The OCM is part of 
a centralized platform that includes participating in clinical labo-
ratory assessments, central data submission and management, 
a central imaging repository, and shared standard operating 
procedures. With the development and implementation of such 
standards, any present or future collaborator on OCM projects 
will have an additional dimension of comparative assessment for 
study validation.
FUTURe MODeLiNG CAPABiLiTieS
In addition to the work currently underway to utilize the OCM 
to model the abovementioned cancer types, opportunity exists 
to utilize the OCM to model a wide range of additional cancers. 
While successful in vitro transformation and in vivo tumor forma-
tion has already been demonstrated in the OCM for three cancer 
types (STS, PDAC, and HCC), the ability to induce tumorigenesis 
in any cell type in a temporal and spatial manner provides the 
framework for modeling cancer types of all origins. While an 
exhaustive attempt to isolate and transform all OCM cell types 
has not been performed, to date researchers have not encountered 
an OCM cell isolate that has not been rendered tumorigenic 
following exposure to Cre recombinase (unpublished data; 
Table 2). The ability to transform all OCM cell types attempted to 
date highlights the potential for utilization in studies focused on 
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additional cancer types, including colorectal, ovarian, fallopian 
tube, renal, bladder, and skin cancers.
In addition, the OCM is emerging as an excellent candidate for 
modeling leukemia, lymphoma, and other hematological cancers 
and their clinically associated comorbidities including obesity, 
myelodysplasia, age-related changes, and toxin-induced malig-
nancies. Hematological malignancies in swine—reviewed in 
Ref. (146)—were first reported as early as 1865 (147) but as of yet, 
there is no porcine model of hematological malignancies that can 
be reliably induced and consistently reproduced. There is a wide 
spectrum of potential immunotherapy targets, cellular therapies, 
and gene targets that can be used to eradicate or control malig-
nant hematopoietic stem cells. However, these therapies present 
significant safety challenges for patients that cannot be addressed 
by traditional procedures and require the development of new 
biomarker protocols and test systems, for which the rigorous use 
of large animal species will be required. A significant hindrance 
to development of therapies for hematological malignancies is 
the limited ability to detect, monitor, and quantify the etiology 
of hematological malignancies in  vivo. Indeed, while current 
imaging strategies increase the predictive accuracy of new drug 
candidates, they are unsuitable for evaluating minimal residual 
disease, the foremost problem in current AML therapy. Temporal 
imaging of the OCM over the course of a disease or treatment 
regime would allow researchers a better appreciation of disease 
pathology, response to treatment, and drug pharmacokinetics. 
In addition, the OCM permits access to blood and bone marrow 
components, lymph nodes, spleen, and thymic tissue, allowing 
transformation of these multiple sources of hematopoietic cells. 
Moreover, the recent development of a porcine CD34 monoclonal 
antibody (Ozer et al., 2017, submitted) as well as the cloning of 
additional porcine hematopoietic cytokines and growth factors 
will enable studies of the regulatory aspects of leukemia and 
lymphoma development.
The ability to model these and other cancer types in the OCM 
is further facilitated by the ability to cross the OCM with other 
breeds, such as the Ossabaw, as well as other transgenic porcine 
models like the APC1311 porcine model of familial adenomatous 
polyposis (79). In addition, the successful utilization of CRISPR 
technology in pigs provides the opportunity to add additional 
mutations to the OCM background, allowing modeling of the 
same cancer type with varying underlying driver mutations, as 
well as cancer types with known genetic backgrounds. Finally, 
utilization of nanoparticle delivery systems can be utilized to 
selectively target Cre exposure in vivo to specific organs and cell 
types (148), allowing autochthonous tumor formation of known 
cellular origin. Together, this highlights the current and future 
capabilities of the highly customizable OCM to drive transitional 
cancer research and address unmet clinical needs.
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